Skip to content

RibOSE - Glucose and Resistance Exercise Training

RibOSE - Effects of Glucose Ingestion During Resistance Exercise Training on Ribosomal Biogenesis in Skeletal Muscle

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04545190
Acronym
RibOSE
Enrollment
16
Registered
2020-09-10
Start date
2020-09-01
Completion date
2020-12-20
Last updated
2021-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Strength/resistance training, Glucose supplementation, Skeletal muscle

Brief summary

The aim of the study is to investigate the effects of ingesting glucose during five bouts of resistance exercise on muscle biological charateristics in m. vastus lateralis of moderately trained healthy individuals (20-45 years of age, n=20)

Detailed description

Muscular responses to resistance training vary extensively between humans, with many showing impaired growth. In such individuals, cellular plasticity is compromised, leading to reduced functional and health-beneficial outcomes of training. While this is likely due to a range of determinants, including epigenetic, genetic and physiological variables, recent studies suggest that it involves reduced ability to produce novel ribosomes in response to training. This eventually leads to less pronounced increases in protein synthesis, and thus decreased growth rates, and makes ribosomal content in muscle a potential proxy marker for training-associated muscle hypertrophy. In a recent study, the investigators showed that increased resistance training volume was associated with more pronounced muscle growth, a trait that was associated with increased ribosomal biogenesis. Despite this, \ 50 % of the participants did not exhibit true beneficial effects of increased training volume, which in turn coincided with reduced abilities to accumulate ribosomes. In such individuals, other means are likely necessary to circumvent the negative influence of genetic and epigenetic predispositions on muscle plasticity. Nutrient supplementation stand out as a potential therapy. However, at present, knowledge with regard to this perspective is limited to a selected few nutrients, with protein ingestion being the best studied potential adjuvant, for which adequate intake seems to be essential for achieving optimal muscle growth, potentially being interconnected with ribosomal synthesis. For other nutrients, such as glucose, little is know about their importance for muscle plasticity and ribosomal biogenesis. In cell types such as cultivated kidney cells, exposure to high levels of glucose is an efficient mean to increase ribosomal biogenesis (and growth rates). This suggests that glucose is an important signaling molecule for increasing ribosomal production per se, perhaps acting as a ligand for signaling proteins or by acting to increase energy availability. In the human body (as opposed to cultured cells), glucose may also exert growth-stimulating effects by increasing insulin levels in blood. Overall, it thus seems plausible that glucose intake during resistance training may stimulate ribosomal biogenesis, in turn having beneficial effects for protein synthesis and muscle plasticity, perhaps acting in an additive manner to protein supplementation. At present, we do not know if this is the case, though studies have suggested that glucose ingestion during acute resistance training sessions may reduce training-induced muscle damage without affecting within-session work output (i.e. volume). This lack of knowledge is surprising given the long-standing appreciation of the beneficial effects of glucose intake for endurance performance, acting to delay muscular fatigue.

Interventions

DIETARY_SUPPLEMENTGlucose

To investigate the effects of glucose intake during resistance training on muscle biological adaptations

Sponsors

Inland Norway University of Applied Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

On each intervention day, participants will receive boluses of supplements in accordance with his or her study ID number. The list that links this ID number to the randomization code will be kept with the person who generated the randomization code (and stored on a safe server) until completion of data sampling and cleaning of data on main outcome measures. The person resonsible for generating the randomization code will not be involved in any aspects of data sampling or handling. None of the project collaborators/participants will have access to this list during the intervention or during data handling. Half the participants (n=10) will commence the intervention with GLU on Day 1, while the other half will commence with PLAC (randomized). For participants starting with GLU, half will perform training on their dominant leg, while the other half will perform training on their non-dominant leg. The same will be the case for participants starting with PLAC.

Intervention model description

The study will be conducted as a 12-day placebo-controlled randomized clinical trial. Each day will consist of concomitant dietary intervention and resistance training. The dietary intervention consists of alternating days of ingesting glucose (GLU, 90 g) or placebo (PLAC) in connection with training. Likewise, training consists of alternating days of resistance training of the two legs (using identical training protocols), with Day 1 involving training of the first leg, Day 2 involving training of the second leg, Day 3 involving training of the first leg, etc. In this way, each of the two dietary interventions will be associated with training of one particular leg, allowing within-subject comparisons of the effects of GLU vs PLAC on muscle biology and recovery.

Eligibility

Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Non-smoking * Moderately trained (i.e. having performed 2-8 resistance training sessions per 14 days for the last six months)

Exclusion criteria

* Not able to understand Norwegian * Unstable cardiovascular disease * Illness or injury contradicting heavy strength training * Disabling musculoskeletal disease * Serious mental illness * Allergy to local anaesthesia * Impaired glucose tolerance

Design outcomes

Primary

MeasureTime frameDescription
Total RNA in muscle tissueBefore the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)Total RNA content in m. vastus lateralis (ug per mg tissue)

Secondary

MeasureTime frameDescription
Glucose in blood, after glucose/placebo intakeImmediately before glucose/placebo intake and 30 min, 45 min, 60 min and 195 min after initial glucose/placebo intakeGlucose concentrations in blood (area under the curve), measured before and after intake of glucose/placebo on the two final days of the intervention (one day = glucose; one day = placebo)
Hormone concentrations in blood (after protein intake)Immediately before protein intake and 90 min after protein intakeAbundances of insulin, c-peptide, testosterone, growth hormone, cortisol and inflammatory markers in blood, measured after intake of protein on the two final days of the intervention
Unilateral lower body isokinetic muscle strength (during the intervention)Before the intervention and after the second, fourth and sixth training sessionThe ability of the knee extensors to exert maximal force during isokinetic movements (recovery/strength), measured before the intervention and at three time points during the intervention (\ 24 hours after training sessions)
Unilateral lower body isokinetic muscle strength (last days of the intervention)Before the last training session and 30 min, 120 min and 24 hours after the last training sessionThe ability of the knee extensors to exert maximal force during isokinetic movements (recovery/strength), measured before and at three time points after the last two training sessions (one day = glucose; one day = placebo)
Unilateral lower body isometric muscle strength (during the intervention)Before the intervention and after the second, fourth and sixth training sessionThe ability of the knee extensors to exert maximal force during isometric actions (recovery/strength), measured before the intervention and at three time points during the intervention (\ 24 hours after training sessions)
Unilateral lower body isometric muscle strength (last days of the intervention)Before the last training session and 30 min, 120 min and 24 hours after the last training sessionThe ability of the knee extensors to exert maximal force during isometric actions (recovery/strength), measured before and at three time points after the last two training sessions (one day = glucose; one day = placebo)
Perceived muscle soreness (during the intervention)Before the intervention and 24 hours after each training sessionMuscular soreness measured before the intervention and at three time points during the intervention (\ 24 hours after training sessions) using a VAS-scale from 0 to 10 (0 = no soreness; 10 = maximal soreness)
Perceived feeling of the legs (during the intervention)30 min after each training sessionFeeling of the legs measured immediately after each training session using a 9-point scale (1 = very very good, 9 = very very heavy)
Muscle fractional synthesis rateImmediately after the interventionProtein synthesis rate measured using heavy water (deuterium) and chromatography/spectrometry
Ribosomal RNA in skeletal muscleBefore the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)Abundances of ribosomal RNA species in m. vastus lateralis measured using qPCR
Protein in skeletal muscleBefore the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)Abundances of protein species in m. vastus lateralis measured using Western blotting (e.g. ECM proteins)
Gene expression in skeletal muscleBefore the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)Abundances of mRNA species in m. vastus lateralis measured using qPCR
Glucose in blood (after protein intake)Immediately before protein intake and 45 min and 90 min after protein intakeGlucose concentrations in blood (area under the curve), measured before and after intake of protein on the two final days of the intervention
Hormone concentrations in blood (after glucose/placebo intake)Immediately before glucose/placebo intake and 30 min and 60 min after the initial glucose/placebo intakeAbundances of insulin, c-peptide, testosterone, growth hormone, cortisol and inflammatory markers in blood (area under the curve), measured before and after intake of glucose/placebo on the two final days of the intervention (one day = glucose; one day = placebo)

Other

MeasureTime frameDescription
Dietary registrationDuring each day of the interventionNutritional intake during each day of the intervention, tracked using MyFitnessPal
Unilateral lower body maximal strengthBefore the interventionThe ability of muscles of the lower body to exert maximal force during dynamic movements
Blind test glucose vs placebo comparatorsImmediately after the interventionThe ability to discriminate between glucose and placebo beverages, tested after the training intervention using a blinded randomized design: each participant will ingest six beverages (3 x glucose and 3 x placebo) and will be asked to identify theam as either glucose or placebo. The ability to discriminate will be determined based on analyses of the full study population
Deuterium in spitOn each day of the interventionDeuterium levels in spit on each day during the intervention measured using chromatography/spectrometry (sampled prior to each training session)
Fasting blood glucoseBefore the intervention and immediately after the interventionFasting blood glucose measured in serum, measured before the intervention and prior to training on the last two days of the intervention
Training diaryDuring each training session of the interventionTraining volume (total kg lifted) during each day of the intervention
Body mass compositionPrior to the interventionBody mass composition measured using DXA

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026